ATEBRIOZ

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ATEBRIOZ
Generic name
ZILURGISERTIB
Manufacturer
Mirum Pharmaceuticals Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
f542e4b0-072a-42c6-80c9-5977054971e0
SPL ID
f542e4b0-072a-42c6-80c9-5977054971e0
Version
1
Effective date
2026-09-09
Source export date
2026-11-13
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:02:10
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5. WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity : Can cause fetal harm. Verify females of reproductive potential are not pregnant prior to initiating ATEBRIOZ and advise of the potential risk to a fetus and to use effective contraception. Advise the patient to discontinue ATEBRIOZ immediately if pregnancy occurs during treatment and to contact their healthcare provider. ( 5.1 , 8.1 , 8.3 ) 5.1. Embryo-Fetal Toxicity ATEBRIOZ is contraindicated during pregnancy. Based on its mechanism of action and findings from animal reproduction studies, ATEBRIOZ can cause fetal harm when administered to a pregnant woman. Oral administration of zilurgisertib to pregnant rats during the period of organogenesis resulted in adverse outcomes, including embryofetal lethality, decreased fetal weight, and skeletal malformations at exposures ≥ 3-times the human exposure at the clinical dose of 100 mg. [see Use in Specific Populations ( 8.1 ) and Clinical Pharmacology ( 12.1 )]. For females of reproductive potential, verify that the patient is not pregnant prior to initiation of treatment. Advise females of reproductive potential to use effective contraception during treatment with ATEBRIOZ and for one week after the final dose. Advise patients to discontinue ATEBRIOZ immediately if pregnancy occurs during treatment and to contact their healthcare provider [see Use in Specific Populations ( 8.1 , 8.3 )] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6. ADVERSE REACTIONS Most common adverse reactions (≥ 10%): headache, arthralgia, upper respiratory tract infection, epistaxis, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mirum Pharmaceuticals, Inc. at 1-855-MRM-4YOU or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1. Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ATEBRIOZ was evaluated in a 24-week, multicenter, randomized, double-blind, placebo-controlled trial (Study 1; NCT05090891). Sixty-three patients (28 adults and 35 pediatric patients 12 years of age and older) with FOP were randomized to ATEBRIOZ 100 mg (n = 32) or placebo (n = 31) once daily for 24 weeks. Patients who completed the 24‑week double‑blind period entered the 292-week open-label extension [see Clinical Studies ( 14 )] . The adverse reactions reported by ≥ 10% of ATEBRIOZ-treated adults and pediatric patients aged 12 years and older and more frequently than placebo through Week 24 are listed in Table 1 . Table 1: Adverse Reactions Occurring in ≥ 10% of Adults and Pediatric Patients Aged 12 Years and Older with FOP Receiving ATEBRIOZ and more Frequently than Placebo in Study 1 Through Week 24 Adverse Reaction ATEBRIOZ (N = 32) n (%) Placebo (N = 31) n (%) Headache 7 (22) 5 (16) Arthralgia 7 (22) 3 (10) Upper respiratory tract infection 7 (22) 3 (10) Epistaxis 4 (13) 0 Nausea 4 (13) 1 (3) Clinically Significant Adverse Reactions Occurring in < 10% of Patients with FOP In patients receiving ATEBRIOZ 100 mg orally once daily through Week 24, adverse reactions occurring in < 10% of patients included gastroenteritis, gastroesophageal reflux disease, iron deficiency anemia, rash (3 patients each), and alopecia (2 patients). None of these events were reported in the placebo group. Laboratory Findings Increases in Serum Iron, Hemoglobin, and Transferrin Saturation Compared to placebo, ATEBRIOZ-treated patients experienced mean increases in serum iron, hemoglobin, and transferrin saturation levels; the mean values for all three measures remained within the normal range. No significant differences in mean ferritin change from baseline was observed between ATEBRIOZ- and placebo-treated patients, including patients who took iron supplements. Based on the data through Week 100, the increases in serum iron and transferrin saturation with ATEBRIOZ were not associated with signs or symptoms of iron overload.

adverse reactions table

<table ID="_Ref240883417" width="100%"> <caption>Table 1: Adverse Reactions Occurring in &#x2265; 10% of Adults and Pediatric Patients Aged 12 Years and Older with FOP Receiving ATEBRIOZ and more Frequently than Placebo in Study 1 Through Week 24</caption> <col width="33%"/> <col width="33%"/> <col width="33%"/> <thead> <tr> <th valign="bottom" align="left" styleCode="Rrule Botrule Lrule Toprule "> <content styleCode="bold">Adverse Reaction</content> </th> <th valign="bottom" align="center" styleCode="Rrule Botrule Lrule Toprule "> <content styleCode="bold">ATEBRIOZ</content> <content styleCode="bold">(N = 32)</content> <content styleCode="bold">n (%)</content> </th> <th valign="bottom" align="center" styleCode="Rrule Botrule Lrule Toprule "> <content styleCode="bold">Placebo</content> <content styleCode="bold">(N = 31)</content> <content styleCode="bold">n (%)</content> </th> </tr> </thead> <tbody> <tr> <td valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>Headache</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>7 (22)</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>5 (16)</paragraph> </td> </tr> <tr> <td valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>Arthralgia </paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>7 (22)</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>3 (10)</paragraph> </td> </tr> <tr> <td valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>Upper respiratory tract infection</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>7 (22)</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>3 (10)</paragraph> </td> </tr> <tr> <td valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>Epistaxis</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>4 (13)</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule "> <paragraph>0</paragraph> </td> </tr> <tr> <td valign="bottom" styleCode="Rrule Botrule Lrule Toprule "> <paragraph>Nausea</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule "> <paragraph>4 (13)</paragraph> </td> <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule "> <paragraph>1 (3)</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.